Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
NCT ID: NCT04961138
Last Updated: 2021-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
164 participants
INTERVENTIONAL
2021-08-31
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survival Analysis: TACE vs. Combination Therapy in HCC
NCT06261138
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
NCT02109146
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
NCT02862613
RCT on Adjuvant TACE After Hepatectomy for HCC
NCT01512407
Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
NCT04213118
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neoadjuvant group
Transhepatic Arterial Chemotherapy And Embolization (TACE)
Receiving TACE and lenvatinib before surgery.
Surgery group
Surgery
Removing tumor by surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transhepatic Arterial Chemotherapy And Embolization (TACE)
Receiving TACE and lenvatinib before surgery.
Surgery
Removing tumor by surgery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of stage III hepatocellular carcinoma(HCC)
* Fulfill the criteria of surgery
* No other severe comorbidity
* Eastern Cooperative Oncology Group score(ECOG) 0-2
* Expected survival \> 3months
* Informed consent obtained.
Exclusion Criteria
* Severe cirrhosis with Child-Pugh score \>10
* Total bilirubin \> 1.5 times upper limit, AST or ALT \> 2times upper limit, indocyanine green retention rate after 15 min(ICG15) \>=40%;
* Not fulfill the surgery criteria
* Received major surgery within 1month
* History of other tumor
* Participate other clinical trial within 1month
* Drug or alcohol abuse, AIDS
* Uncontrollable epileptic seizure or cognitive disorder
* Severe allergy
* Other unsuitable conditions.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.